New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Amphastar Pharmaceuticals, Inc.
http://www.amphastar.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amphastar Pharmaceuticals, Inc.
Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps
The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.
Amphastar Has First US Glucagon Rival
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Oncimmune Expands Application Of Liquid Biopsy Auto-Antibody Technology
The company’s liquid biopsy test business is complemented by a patient-stratification service for pharmaceutical companies.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
- Pulmonary
- Other Names / Subsidiaries
-
- Amphastar France Pharmaceuticals (AFP)
- Armstrong Pharmaceuticals, Inc.
- International Medication Systems (IMS)
- Nanjing Puyan Pharmaceutical Technology (ANP)